World's Best Scientists 2026 revealed!
Michel Attal

Michel Attal

D-Index & Metrics

Medicine

D-Index
117
Citations
58961
World Ranking
4164
National Ranking
42

Michel Attal publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michel Attal sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 513 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michel Attal D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michel Attal sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 117 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michel Attal is affiliated with Janssen (Belgium) in Belgium, contributing to research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work focuses largely on Hematology, Molecular Biology, and Oncology, with emphasis on subfields such as Genetics and Radiology, Nuclear Medicine and Imaging.

The research topics most frequently addressed by Michel Attal include:

  • Multiple Myeloma Research and Treatments
  • Cancer Treatment and Pharmacology
  • Protein Degradation and Inhibitors
  • Histone Deacetylase Inhibitors Research
  • Peptidase Inhibition and Analysis
  • Monoclonal and Polyclonal Antibodies Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Michel Attal has published extensively in various venues, with frequent publications in:

  • Blood
  • Journal of Clinical Oncology
  • Haematologica
  • British Journal of Haematology
  • New England Journal of Medicine

Frequent coauthors collaborating with Michel Attal include:

  • Philippe Moreau
  • Hervé Avet-Loiseau
  • Thierry Façon
  • Aurore Perrot
  • Xavier Leleu

Among their recent papers are:

  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma, 2022, New England Journal of Medicine
  • Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma, 2020, Journal of Clinical Oncology
  • Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial, 2020, Blood
  • Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma, 2020, Blood Cancer Journal
  • Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma, 2020, Leukemia & lymphoma/Leukemia and lymphoma

Their academic output demonstrates a concentrated focus on multiple myeloma and related therapeutic strategies, continuously contributing to advances in hematological cancer treatment through clinical research and follow-up studies.

Best Publications

  • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

    Michel Attal;Jean-Luc Harousseau;Anne-Marie Stoppa;Jean-Jacques Sotto

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot

  • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

    Thierry Facon;Jean Yves Mary;Cyrille Hulin;Lotfi Benboubker

  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Michel Attal;Valerie Lauwers-Cances;Cyrille Hulin;Xavier Leleu

  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

    Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

    Niccolo Bolli;Hervé Avet-Loiseau;David C. Wedge;Peter Van Loo

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano

  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

    Michel Attal;Jean-Luc Harousseau;Serge Leyvraz;Chantal Doyen

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial

    Philippe Moreau;Thierry Facon;Michel Attal;Cyrille Hulin

  • Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

    Jean-Luc Harousseau;Michel Attal;Hervé Avet-Loiseau;Gerald Marit

  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

    Philip L. McCarthy;Sarah A. Holstein;Maria Teresa Petrucci;Paul G. Richardson

  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Commentary

    Giampaolo Merlini;Michel Attal;Jean-Luc Harousseau;Serge Leyvraz

Frequent Co-Authors

Thierry Facon
Thierry Facon Centre Hospitalier Régional et Universitaire de Lille
Philippe Moreau
Philippe Moreau University of Nantes
Denis Caillot
Denis Caillot Grenoble Alpes University
Jean-Luc Harousseau
Jean-Luc Harousseau University of Nantes
Xavier Leleu
Xavier Leleu Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Mauricette Michallet
Mauricette Michallet University of Helsinki
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA offers a wide spectrum of online degree options and flexible learning pathways. For those interested in leadership roles in hospitals or clinics, an healthcare administration accelerated degree can fast-track your entry into healthcare management. These programs are designed for busy professionals seeking to grow into leadership positions quickly.

Registered nurses aiming to advance their careers can consider specialized RN to NP bridge programs, which enable RNs to become nurse practitioners through online study options. Nutrition is another growing field; earning an online degree nutrition can open doors to roles in clinical practice, wellness coaching, and community health.

It’s essential to choose programs with proper accreditation to ensure educational quality. If you’re exploring which online healthcare degree programs are recognized for their accreditation by CAHME, check out reputable schools that meet these standards for Master of Health Administration (MHA) degrees. Your choice of program will impact both your career prospects and eligibility for future licensing or certification.

Best Scientists Citing Michel Attal

Trending Scientists

Recently Published Articles